The BEVANEC phase 2 trial in EP-PD-NEC, predominantly with Ki-67 > 55% (85%), demonstrated that the addition of bevacizumab (5 mg/kg) to FOLFIRI did not improve the response rate (25.5% vs. 18.3%) or OS at 6 months (53% vs. 60%) [14]. Here, MKI67 is linked to neuroendocrine carcinoma.